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Background: Hyperphosphatemic Familial Tumoral Calcinosis (HFTC) and Hyperphosphatemic Hyperostosis Syndrome
(HHS) are associated with autosomal recessive mutations in three different genes, FGF23, GALNT3 and KL, leading to
reduced levels of fibroblast growth factor 23 (FGF23) and subsequent clinical effects.
Results: We describe a consanguineous family with two affected siblings with HFTC and HHS caused by a novel
homozygous G-to T substitution in exon 3 of GALNT3 (c.767 G > T; p.Gly256Val), demonstrating great phenotypic
variation and long asymptomatic intervals. Calcific tumors appeared at 14 years of age in the male, and the female
displayed episodic diaphysitis from age 9 years. Symptoms of eye involvement were present in both from childhood,
and progressed into band keratopathy in the female. Abnormal dental roots and tooth loss, as well as myalgia were
present in both from their mid-twenties, while the female also had calcifications in the placenta, the iliac vessels and
thyroid cartilage. New calcific tumors appeared more than 20 years after the initial episodes, delaying diagnosis and
treatment until the ages of 37 and 50 years, respectively. Both siblings had elevated serum phosphate levels, inappropriately
elevated tubular maximum phosphate reabsorption per unit glomerular filtration rate (TmP/GFR), reduced levels of intact
FGF23 and increased levels of c-terminal FGF23. Review of all 54 previously published cases of GALNT3, FGF23,
and KL associated HFTC and HHS demonstrated that more subjects than previously recognized have a combined
phenotype.
Conclusion: We have described HFTC and HHS in a consanguineous Caucasian family with a novel GALNT3 mutation,
demonstrating new phenotypic features and significant variability in the natural course of the disease. A review of the
literature, show that more subjects than previously recognized have a combined phenotype of HFTC and HHS. HHS
and HFTC are two distinct phenotypes in a spectrum of GALNT3 mutation related calcification disorders, where the
additional factors determining the phenotypic expression, are yet to be clarified.
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The last decade has brought new insight into the molecular
and pathophysiological aspects of phosphate metabolism.
Previously, the regulation of serum and body phosphate
was thought to be merely a consequence of the regulation
of calcium levels by parathyroid hormone (PTH) and vita-
min D. It is now accepted that the regulation of phosphate
is specific, and involves phosphatonins, in particular fibro-
blast growth factor 23 (FGF23) [1].
Hyperphosphatemic familial tumoral calcinosis (HFTC) is
a rare monogenic disorder with disturbances in the hormo-
nal regulation of phosphate levels by FGF23, leading to soft
tissue calcifications [2]. Hyperphosphatemic hyperostosis
syndrome (HHS) is characterized by hyperphosphatemia
and episodes of diaphysitis and cortical hyperostosis visual-
ized on x-rays. This was thought to be a separate entity,
rarely occurring together with HFTC, but it has later been
shown that the same genes and same mutations are involved
in both HHS and HFTC. This has led to the current opin-
ion, that HHS and HFTC are different manifestations of the
same genetic defect, and that in some families the same mu-
tation can lead to either phenotype [3-5]. Both conditions
are caused by inactivating mutations in either the FGF23
gene encoding the phosphaturic hormone FGF23 [6,7], or
the GALNT3 gene encoding the UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase
3 (GalNAc-T3) enzyme [8]. This enzyme is necessary
to glycosylate FGF23, thereby preventing the break
down and inactivation of the functional full-length ver-
sion of the protein [9]. There is also one report of
HFTC caused by an inactivating mutation in the KL
gene, encoding α-Klotho, which is an essential co re-
ceptor for the FGF23 receptor function in phosphate
regulation [10].
GALNT3-associated HHS and HFTC are rarely found
in Caucasians [11]. In this report we describe a consan-
guineous family of Norwegian origin, with a novel
homozygous mutation in exon 3 of GALNT3, where
diagnosis and treatment were delayed until late adult-
hood. In addition to new phenotypic features, the cases
demonstrate the significant variability in the natural
course of the disease, and how features of HFTC and
HHS can be substantially overlapping with time, even
in the same patient.Methods
Patients
The family was recruited from a national population-based
cohort of familial hyperphosphatemia in Norway. Written
informed consent was obtained from all study participants.
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Region West, Norway
(REK number 2009/1140).Biochemical parameters
Blood samples were collected after an overnight fast.
Circulating levels of calcium, albumin, phosphate and al-
kaline phosphatase (ALP) activity in serum were analyzed
using the Modular P-system from Roche Diagnostics
(Basel, Switzerland). PTH was measured with a two-site
chemiluminescent enzyme-labeled immunometric assay for
intact PTH (Immulite 2000, Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA). Measurement of 25(OH)D levels
was performed using an in-house developed liquid chroma-
tography double mass spectrometry (LC-MS/MS) method
[12]. A spot sample of urine collected at the time of blood
sampling was analyzed for calcium, phosphorus and cre-
atinine. The maximal tubular reabsorption of phosphate
per glomerular filtration rate (TmP/GFR) was calculated
according to the algorithm based on the nomogram of
Walton and Bijvoet [13,14]. Plasma intact FGF23 (iFGF23)
was measured with the FGF23-ELISA kit (Kainos Labora-
tories, Japan), with a lower detection limit of 3 pg/ml and a
coefficient of variation (CV) of 4%. Plasma C-terminal
FGF23 (cFGF23) was measured using the FGF23 sec-
ond generation C-terminal ELISA kit (Immutopics, San
Clemente, CA, USA), with a lower detection limit of 1.5
RU/ml and a CV of 4.7%.
Bone mineral density
The bone mineral density (BMD) of the right hip and
lumbar spine was measured with dual X-ray absorpti-
ometry (DXA) using Hologic Delphi W (Hologic inc.,
Bedford, Massachusetts, USA).
Genetic analysis
Genomic DNA was purified from blood using the Qia-
Symphony system (Qiagen, Hilden, Germany).
All exons and intron-exon boundaries, of GALNT3, KL
and FGF23 were sequenced in subject 1 (the index case).
Only exon 3 of GALNT3 was sequenced in subject 2 as well
as in the 7 asymptomatic family members (Subjects I-2,
II-2, II-4, III-1, III-3, IV-1, IV-2 in Figure 1) and 192
healthy blood donors.
DNA targets were first amplified by polymerase chain re-
action (PCR) (list of primers available upon request) using
the AmpliTaq Gold® DNA polymerase system (Applied bio-
systems, Life biosystems, Carlsbad, California, USA. PCR
amplicons were purified with 2 μl of ExoSapIT®. Using the
Big Dye Terminator® chemistry sequencing was performed
on the 3730 DNA analyzer, (Applied biosystems) and ana-
lyzed using the SeqScape® software (Applied biosystems).
Strategy of the literature review
We searched PubMed and EmBase for case reports on
HFTC and HHS caused by mutations in GALNT3, FGF23
and KL using the search terms “hyperphosphatemic tumoral
calcinosis”, “hyperphosphatemia hyperostosis syndrome”,
Figure 1 Pedigree.
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tion”. Some cases and pedigrees were described in several
papers, including earlier papers on the clinical presentation
and later papers describing disease progression and genetic
diagnose. In these cases we included all papers. We did not
include case reports describing pedigrees or cases where a
genetic diagnosis was not made.
Results
Case reports
Subject 1 is a Caucasian male, the youngest of five siblings
of a consanguineous marriage (Table 1); the parents have
a common ancestor eight generations back. He presented
with a calcified mass on his right elbow at age 14. This
mass was removed, the histological diagnosis was tumoral
calcinosis, but no treatment or follow up was initiated.
Prior to this episode he had chronic conjunctival irritation
and abnormal dental roots shown on x-ray. Dental ab-
scesses and spontaneous tooth loss started at 25 years of
age. There were no new calcific tumors until the age of 35,
when he developed a tender mass in his left gluteal area.
He was eventually diagnosed with HFTC at age 37, when
he presented with a 6 × 8 cm calcification over his left
ischial tuberosity (Figure 2a), hyperphosphatemia, an in-
appropriately high TmP/GFR of 1.46 and TRP 84%. His
renal function and serum calcium were normal. Serum
1,25 dihydroxyvitamin D3 was inappropriately normal in
the setting of hyperphosphatemia and serum intact PTH
was low (Table 2). Therapy with the phosphate binder
Sevelamer 1600 mg three times daily was started, but the
patient discontinued medication after one year due to non-Table 1 FGF23 levels
Individual1 Ref. range Unit I-2 II-2
Genotype2 M/m M/m
i-FGF23 21.6-70.23 pg/ml 66.3 51
c-FGF23 10-802 RU/ml 32.2 25.2
1Individuals, as presented in Figure 1.
2M = wild-type allele; m = mutant allele.
3Reference range valid for the laboratory used for this study.medical circumstances. At age 41 his left gluteal mass had
increased further, to the degree that it restricted his daily
activity. Spontaneous rupture of the overlying skin resulted
in discharge of a white matter and transient pain relief, but
there was rapid relapse. Sevelamer 4.8-6.4 g per day was
tried once again, but had no effect on tumor size or serum
phosphate levels.
At 42 years old his left gluteal mass had not decreased
despite treatment for one year. He had general myalgia,
with pain and stiffness in calves and forearms after slight
activity. Clinical examination revealed a large, tender
mass in the left gluteal area, displacing the natal cleft to
the right, and the calves felt hard on palpation. Eye exam-
ination revealed salt-like conjunctival deposits. All his per-
manent teeth had been substituted by implants, but dental
health was otherwise good. His height was 172.2 cm, head
circumference was 59 cm and blood pressure was 110/
80 mmHg. Computerized tomography of the kidneys and
abdomen was normal. Bone mineral density (BMD) of the
femoral neck and total hip was relatively high (T-scores
1.3 and 1.9; Z-scores 1.9 and 2.2, respectively), while lum-
bar spine BMD was normal (T-score 0.4; Z-score 0.5). In
conclusion, he has had manifestations of classic HFTC
from childhood. The long interval between development
of calcific tumors has delayed diagnosis and treatment.
Subject 2 is the older sister of subject 1. She was diag-
nosed with HFTC at the age of 50 upon serum phosphate
screening of the first-degree relatives of subject 1. A re-
view of her past medical record revealed an episode of
several cutaneous tumors on her scalp at three weeks of
age. At age six years she had a large tumor in the glutealII-3 II-4 II-5 III-1 III-3
m/m M/M m/m M/M M/m
26.8 33.0 12 47.2 53
120 34.8 210 17.2 20.2
Figure 2 Radiographic findings. The pictures show a) the left gluteal calcification in subject 1, and b) age-inappropriate thyroid cartilage
calcifications in subject 2.
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thigh; both tumors were incised, but no diagnose is
noted in her medical records. Between the ages of nine
and 12 years, she had three episodes of unilateral leg
pain lasting for several weeks and treated with antibi-
otics for suspected osteomyelitis; blood cultures were
sterile and x-rays showed sclerosis of the tibia and peri-
osteal thickening with onionskin configuration. At age
25 she had a new episode of leg pain, but this time the
radiological examinations were negative, and she received
no treatment. From her twenties, she has had conjunctival
irritation and dental problems similar to her brother. At
age 22 she gave birth to a healthy boy one week before
term date after an uneventful pregnancy; the placenta was
highly calcified, but the baby had no signs of intrauterine
growth restriction (birth weight 3400 g, length 51 cm,
head circumference 36 cm). Her second pregnancy was
uncomplicated, but birth records are not available. She has




Unit Subject 1 Subject 2
T1 T2 T1 T2
s-Phosphate M: 0.85-1.65 mmol/L 1.81 2.21
F: 0.85-1.50 1.6 – 1.84 1.36
s-Calcium 2.15-2.51 mmol/L 2.37 2.36 2.5 2.64
s-iPTH 1.6-6.9 pmol/L 0.8 1.4 NA 5.2
s-Creatinine M: 60-105 μmol/L 72 78
F: 45-90 73 61
i-FGF23 26.1-70.21 pg/ml NA 12 NA 26.8
c-FGF23 10-801 RU/ml NA 210 NA 120
1,25(OH)2 vit D 50-150 nmol/L 85 87 NA 54
TmP/GFR > 0.85 mmol/L 1.46 2.07 1.41 1.12
TRP > 80 % 84 94 88 82.5
1Reference range valid for the laboratory used for this study.In adulthood her chief complaint has been myalgia,
stiffness of knees, hips and shoulders, and pain and de-
formities of her fingers and feet. The clinical findings re-
sembled osteoarthritis, but the rheumatologic diagnostic
work up was inconclusive. X-rays showed pronounced
calcifications and degenerative changes in and around
the phalanges of her hands and feet, calcifications of soft
tissues in the foot, large bilateral calcaneal enthesopathies
and age-inappropriate calcification of the thyroid cartilage
(Figure 2b). Blood tests at age 50 (Table 2) revealed hyper-
phosphatemia, normal kidney function and inappropriately
elevated renal tubular reabsorption of phosphate. The serum
level of calcium was slightly elevated, but the serum levels of
PTH and 1.25 (OH)2 vitamin D3 were not available.
At 55 years of age she had been treated with Sevelamer
800 mg per day for the previous three years, and both her
symptoms and serum phosphate level had remained stable.
Clinical examination revealed a height of 163.3 cm, head
circumference was 56 cm and blood pressure was 120/
70 mmHg. She had salt-like deposits on her bulbal con-
junctiva, and the ophthalmology report confirmed band
keratopathy but normal vision. She had some dental im-
plants but good dental health. Findings in her hands, knees
and hips were as previously noted. In addition her calves
felt stiff on palpation. Computerized urography showed
normal kidneys, but calcifications in the iliac vessels. BMDs
of the femoral neck, total hip and lumbar spine were all
normal (T-scores 1.5, 0.5 and 0.4; Z-scores 2.6, 1.2 and 1.5,
respectively). We conclude in retrospect that she first man-
ifested symptoms HHS in childhood, and that the absence
of calcific tumors has led to delayed diagnosis.
Biochemical profile at the time of diagnosis and inclu-
sion is given in Table 2.
FGF23
The plasma intact and c-terminal FGF23 were measured
at enrolment. The level of intact FGF23 was decreased
and c-terminal FGF23 was elevated in the two affected
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pronounced in the male than in the female. The unaffected
healthy family members had normal levels of iFGF23 and
cFGF23 (Table 1).
Genetic analysis
Subject 1 was screened for mutations in all exons of FGF23,
GALNT3 and KL. No mutations were found in FGF23 or
KL, but a novel homozygous G-to T substitution in exon 3
of GALNT3 (c.767 G>T) was identified, resulting in an
amino acid change in position 256 (p.Gly256Val) (Figure 3).
Subject 2 was also homozygous for this mutation, while
her son and mother were heterozygous carriers. Subjects
II-2, II-4, III-1, IV-1 and IV-2 did not carry the mutation.
This substitution was not found in 192 healthy blood
donors.
The detected mutation is not described in available data-
bases and both the nucleotide and amino acid positions are
highly conserved (phyloP: 5.86 and conserved up to C. ele-
gans), and the variant is predicted as pathogenic by several
prediction programs such as Polyphen2 [15], Align GVGD,
MutationTaster and SIFT.
Review of the literature
A summary of all articles describing HFTC and HHS in
subjects with GALNT3, FGF23 and KL mutation is given
in Additional file 1: Table S1.
In addition to the two subjects in this report, our search
of the literature identified a total of 40 articles describing
54 affected subjects. This gives a total of 56 subjects (30
male; 26 female) from 35 different pedigrees. In 12 of the
previously described cases of HFTC and one of the cases
of HHS, we found that the cases had actually a com-
bined phenotype of HFTC + HHS (“Phenotype revised”
in Additional file 1: Table S1).Figure 3 GALNT3 variations [3,4,8,11,18,22,26-36]. The figure shows the
HHS. The amino acid changes are placed in boxes corresponding to the ob
red box means the combined phenotype HFTC + HHS. Mutations placed ab
missense mutations are placed below the figure. The orange box represen
represents the glycosyl transferase domain (aa 188–374), and the light blue
area represents the glycosyl transferase superfamily domain (aa 163–496).Genotype and phenotype
GALNT3 mutations were identified in 42 cases (22 men,
20 female; 75%) (Figure 3), FGF23 mutations in 13 cases
(8 male, 5 female; 23%), and a KL mutation was found in
one female subject (2%). HFTC was the dominating
phenotype in subjects with GALNT3 mutations, whereas
in subjects with FGF23 mutation, HFTC and the com-
bined HFTC +HHS phenotype were equally represented
(Table 3). Interestingly, the isolated HHS phenotype was
not found in subjects with FGF23 mutation. Dental in-
volvement was reported more often in subjects GALNT3
than FGF23 mutation (43% and 23%, respectively), whereas
vascular calcification seemed more common with FGF23
mutation than with GALNT3 mutation (23% and 14%,
respectively). Eye involvement was reported equally with
both genotypes.Sex and phenotype
Overall, males tend to have the phenotype of classic
HFTC (60% of men), while females more often have mani-
festations of hyperostosis (HHS alone or HFTC+HHS; 56%
of women) (Table 3). Vascular calcification was assessed in
18 cases, and was reported to occur more often in females
than in males, whereas dental and eye involvement were re-
ported more often in males (43% and 20% of the males and
32% and 12% of the females, respectively).Discussion
We describe a consanguineous Caucasian family with two
affected siblings carrying a novel homozygous missense
mutation in exon 3 of the GALNT3 gene. The male has
classic HFTC and the female had one episode of cutane-
ous nodules on her scalp in infancy and episodes of HHS
in childhood.position of the amino acid changes associated with HFTC and/or
served phenotype; green box means HHS, blue box means HFTC and
ove the figure are predicted to damage protein function, while
ts the transmembrane domain (TM, aa 20–37), the light red box
box represents the ricin-B-lectin domain (aa 497–630). The shaded
Table 3 Review of the literature [3,4,7,8,11,16-49]
Phenotype Total Genotype Sex1
GALNT3 FGF23 KL Male Female
N (%) N (%) N (%) N (%) N (%) N (%)
Total 56 (100) 42 (75) 13 (23) 1 (2) 30 (54) 25 (46)
Male 29 (54) 22 (52) 8 (64) 0 (0)
Female 25 (46) 20 (48) 5 (36) 1 (100)
HFTC 30 (54) 22 (52) 8 (62) 0 18 (60) 12 (48)
HHS 6 (11) 6 (14) 0 0 3 (10) 3 (12)
HFTC + HHS 20 (36) 14 (33) 5 (39) 1 9 (30) 10 (40)
Dental involvement 22 (39) 18 (43) 3 (23) 1 13 (43) 8 (32)
Vascular calcification 10 (18) 6 (14) 3 (23) 1 3 (10) 6 (24)
Eye involvement 9 (16) 7 (17) 2 (15) 0 6 (20) 3 (12)
1Between-sex comparison for GALNT3 and FGF23 mutation only.
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21 cases have been described in the literature [16,50-54],
and of these only three previous cases have been associ-
ated with elevated serum phosphate levels [16,55,56].
The genetic mutations of previously described cases are
unknown. Subject 2 had subcutaneous tumors on her
scalp at the age of three weeks, which may have been the
first manifestations of HFTC in this patient, with new
tumors developing on her gluteal area at six years and
thigh at seven years. There are examples of asymptomatic
hyperphosphatemic children, who developed HFTC some
years after hyperphosphatemia was first identified [57],
and in one family, a small child, with homozygous muta-
tion in FGF23, was hyperphosphatemic but asymptomatic,
in contrast to her older sister with HFTC [17]. Our review
of the literature shows that HFTC and HHS rarely mani-
fested before the age of two years, with 78% of cases pre-
senting between two and 13 years of age. The symptoms
displayed in subject 2 in infancy may reflect GALNT3 as-
sociated HFTC. This condition may be under-diagnosed
in small children.
In our family, the clinical picture was complex and var-
ied significantly with age. Band keratopathy, not previously
reported in GALNT3 associated HFTC or HHS, was found
in the female at age 52. Eye involvement, with irritated,
itchy eyes, has been present in both siblings since early
childhood, but visual acuity has not been affected. There is
only one previous report of band keratopathy associated
with HFTC, but in that case the mutation was not known
[58]. Reported eye manifestations in HFTC and HHS also
includes calcifications on the eyelids, conjunctiva and the
peripheral cornea [11,18-20] as well as angioid streaks of
the retina [19,21,22]. Angioid streaks represent linear
breaks in areas of calcification of the Bruch’s membrane
separating the retina from the choroid, and may be com-
plicated by retinal detachment are typically found in pseu-
doxanthoma elasticum, a disorder of ectopic calcification.Conjunctival and corneal calcification (CCC) is a well-
known manifestation of metastatic calcification in end
stage renal disease (ESRD) [59]. CCC occurs when the
level of calcium and phosphate in tears approach their
solubility product. As tears evaporate, and the fluid is
concentrated, the result is deposition of calcium-phosphate
salts on the corneal surface in the exposed interpalpebral
region. It is most often located in the perilimbal region,
and does not affect visual acuity. However, the most severe
form, band keratopathy, can lead to visual impairment. In
ESRD, the severity of CCC is positively correlated to the
serum level of phosphate and the serum calcium × phos-
phate product, but not serum calcium levels [60,61]. CCC
is also positively correlated to the occurrence of vascular
calcification in ESRD [61]. The mechanisms of conjunctival
and corneal calcifications are probably the same in HFTC
and HHS, with a high calcium × phosphate product in
serum and also other body fluids, such as tears. Our fe-
male subject is the first reported case of band keratopa-
thy in GALNT3 associated HFTC and HHS, and this
outcome is probably the result of 50 years of untreated
hyperphosphatemia.
Both our subjects have had severe dental involvement.
From childhood their dental roots have been reported as
abnormally short and bulbous, and from about 25 years
age, their teeth started falling out despite good oral hygiene
and regular dental care. Typical dental findings in HFTC
and HHS are short, abnormal roots and obliteration of the
root canals and pulp chambers. The lesions only partly re-
semble dentin dysplasia type I and II [23,24], and the specific
dental lesion has been suggested as a phenotypic marker of
HFTC [62].
The female had pain and stiffness in her hands and feet
going on for several years, along with other diffuse symp-
toms, suggesting a rheumatologic disease. Thorough work-
up failed to find an explanation, however, and the diagnosis
of HFTC/HHS was not suspected until a calcified tumor
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of this disease: firstly, it is very rare, and even more so in
Caucasians, and many clinicians will not be familiar with
the symptoms and signs of the disease. This can lead to de-
layed diagnosis, as well as lack of recognition of complica-
tions of the disease. Second, in HFTC, there are often long
symptom free intervals. This is most likely not associated
with phosphate lowering treatment, but a feature of the
disease [25].
In the first of her two pregnancies, the medical record
describes pronounced placental calcifications. Placenta cal-
cifications have not previously been reported in GALNT3
associated HHS/HFTC. However, placental calcifications
was also reported in a Caucasian female with HFTC [19] in
whom genetic analysis later revealed mutation in FGF23
[63]. Immunohistochemistry has shown a strong level of
antibody staining for GalNAc-T3 in the Golgi apparatus
and nuclei of normal human trophoblastic cells [64], and
recent reports show evidence for the expression of the
FGF receptor and its cofactor α-klotho in murine pla-
centa [65]. These observations may support the hypoth-
esis that HFTC/HHS may be associated with placenta
calcifications. However, further studies are needed to
examine the prevalence of placenta calcifications and
possible placenta failure in human GALNT3 and FGF23
associated HFTC/HHS.
The female had age-inappropriate thyroid calcifications,
but no clinical or biochemical symptoms or signs of thyroid
dysfunction. This same feature has been described in one
previous case of HFTC due to GALNT3 mutation [26].
Both subjects had low levels of plasma intact FGF23
and elevated levels of c-terminal FGF23. This is in con-
cordance with previous findings in HFTC and HHS,
although in our cases the results deviated less from nor-
mal than in previously reported cases (Additional file 1:
Table S1). GALNT3 encodes the enzyme GalNacT3 re-
sponsible for O-linked glycosylation FGF23, thereby
preventing the break down and inactivation of the func-
tional full-length version of the protein [9]. Defective O-
glycosylation of FGF23 due to GALNT3 mutation, as well
as mutation in the FGF23 gene itself, will destabilize the
FGF23 protein and lead to increased levels of FGF23 break
down products. The level of c-terminal FGF23 will be in-
creased, whereas the level of intact FGF23 will be low or
inappropriately normal given the level of hyperphosphate-
mia. The explanation of the relatively less abnormal results
for our two subjects is not clear, but could be due to sam-
pling procedure, sample handling and transportation, or
the different kits used for the analyses, as well as large
inter-individual differences in FGF23 levels [66].
HFTC and HHS, previously described as separate entities,
are now recognized as different manifestations of the same
rare disease [4] of increased phosphate reabsorption from
the kidney proximal tubuli. Some subjects display featuresof both phenotypes, whereas most have HFTC or HHS
[27]. Some authors suggest a correlation between the type
of mutation in the GALNT3 gene and the phenotype [28];
most cases of homozygous missense mutations tend to
have a HHS phenotype, while cases of homozygous non-
sense mutations have a phenotype of HFTC. In our cases,
however, the homozygous missense mutation has resulted
in a HFTC phenotype in the male, and a combined HHS/
HFTC phenotype in the female. Our review of all cases
of HFTC and/or HHS caused by mutations in GALNT3
showed that more cases than previously recognized had
symptoms of HHS in addition to HFTC, and that HFTC
seems to the dominating phenotype in males, while more
females than males have manifestations of both HFTC
and HHS. Our cases confirms the notion that there may
be an underestimate of the prevalence of subjects with
both phenotypes, as subject 2 in our material had symp-
toms of HFTC in infancy, and episodes of HHS in child-
hood, which remained unrecognized until the present
study was conducted. The explanation for the great vari-
ation in phenotype, also within the same family, is not
clear, and influence from different factors regulating calci-
fication needs further clarification.
Conclusion
We have described HFTC and HHS in a consanguineous
Caucasian family with a novel GALNT3 mutation, dem-
onstrating new phenotypic features and significant vari-
ability in the natural course of the disease. A review of
the literature shows that more subjects than previously
recognized have a combined phenotype of HFTC and HHS.
HHS and HFTC are two characteristic phenotypes in a
spectrum of GALNT3 mutation related calcification
disorders, where the additional factors determining the
phenotypic expression, are yet to be clarified.
Additional file
Additional file 1: Table S1. Review of the literature.
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